Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease

Background-Ipratropium is commonly used for the management of elderly patie nts with obstructive airway disease. However, a recent report suggested tha t its use might be associated with a significant increase in mortality. A s tudy was therefore conducted to compare all-cause mortality rates between u sers and nonusers of ipratropium in elderly patients with either asthma or chronic obstructive pulmonary disease (COPD). Methods-A retrospective cohort study was performed using linked data from t he Canadian Institute for Health Information, the Ontario Drug Benefit Prog ram, the Ontario Health Insurance Plan, and the Ontario Registered Persons database. A total of 32 393 patients were identified who were aged 65 years or older and who had been discharged from hospital with asthma or COPD bet ween 1 April 1992 and 31 March 1997. All-cause mortality rates were compare d between those treated and those not treated with ipratropium following di scharge from hospital. Results-In total, 49% of patients received ipratropium within 90 days of di scharge. After adjusting for age, sex, comorbidity, use of health services, and other airway medications there was no significant association in patie nts with COPD between the use of ipratropium and mortality (relative risk ( RR) 1.03; 95% confidence interval (CI) 0.98 to 1.08). In patients with asth ma, however, there was a slight increase in the relative risk of mortality associated with the use of ipratropium (RR 1.24; 95% CI 1.11 to 1.39). A do se-response increase in the mortality rate was not observed with increasing use of ipratropium in either COPD or asthma. Conclusions-The use of ipratropium in patients with COPD was not associated with an increase in mortality. However, in asthma there was a small increa se in the mortality rate. Since asthmatic patients who received ipratropium had greater use of other airway medications and health services, the diffe rence in mortality rate between users and non-users may be a reflection of unmeasured differences in asthma severity.